Entera Bio appoints Miranda Toledano as CFO, CBO, and Head of Corp Strategy; prior CFO Ratan departs

Entera Bio Ltd.

Miranda Toledano appointed Chief Business Officer, CFO, and Head of Corporate Strategy effective May 16, 2022.
Toledano loses independence; no longer serves on Compensation or Audit Committees; vacancies to be filled.
Annual employer cost of $350,000; options for 500k shares at $2.02, vesting over 4 years (25% at year 1).
Prior CFO Ramesh Ratan no longer with company; Dana Yaacov-Garbeli remains as principal accounting officer.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Miranda J. Toledano

Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy

ENTXW · Entera Bio Ltd.

Effective: 2022-05-16
Filed: May 16, 2022, 7:59 PM ET

appointed Ms. Miranda J. Toledano, one of the Company’s existing directors, to serve as the Company’s Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy, effective as of May 16, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Miranda J. Toledano was appointed as Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy at Entera Bio Ltd..

Action: appointed
Role: Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy

Exact text from the filing

appointed Ms. Miranda J. Toledano, one of the Company’s existing directors, to serve as the Company’s Chief Business Officer, Chief Financial Officer and Head of Corporate Strategy, effective as of May 16, 2022

View on SEC.gov

Entera Bio Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-22-001980

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.